Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vericiguat

FDA-approved product (tablet, oral), marketed as Verquvo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vericiguat
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Heart failure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other vasodilators used in cardiac diseases
FDA pharmacologic class
Soluble Guanylate Cyclase Stimulator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vericiguat in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vericiguat with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

    NCT05711719 · start 2023-06-16

    Registered record
    Registry ID
    NCT05711719
    Conditions
    Metabolic Syndrome; Coronary Microvascular Dysfunction
    Interventions
    Vericiguat; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-06-16
    Completion
    2025-11-18
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Syndrome; Coronary Microvascular Dysfunction
    InterventionVericiguat; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

    NCT05714085 · start 2023-05-31

    Registered record
    Registry ID
    NCT05714085
    Conditions
    Heart Failure; Left Ventricular Systolic Dysfunction
    Interventions
    Vericiguat tablet; Vericiguat suspension; Placebo tablet; Placebo suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2023-05-31
    Completion
    2032-04-15
    Enrolment
    342

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Left Ventricular Systolic Dysfunction
    InterventionVericiguat tablet; Vericiguat suspension; Placebo tablet; Placebo suspension
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery

    NCT05812755 · start 2023-05-19

    Registered record
    Registry ID
    NCT05812755
    Conditions
    Endothelial Dysfunction; Vascular Diseases; Kidney Injury; Brain Disease; Vascular Inflammation
    Interventions
    Vericiguat; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-05-19
    Completion
    2029-07
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndothelial Dysfunction; Vascular Diseases; Kidney Injury; Brain Disease +1 more
    InterventionVericiguat; Placebo
    PhasePhase 4
    Registry statusRecruiting

  • The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

    NCT05420012 · start 2023-05-01

    Registered record
    Registry ID
    NCT05420012
    Conditions
    Heart Failure; Heart Failure With Reduced Ejection Fraction (HFrEF)
    Interventions
    Vericiguat; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-05-01
    Completion
    2024-10-24
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Heart Failure With Reduced Ejection Fraction (HFrEF)
    InterventionVericiguat; Placebo
    PhasePhase 4
    Registry statusCompleted

  • An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China

    NCT05728502 · start 2023-04-25

    Registered record
    Registry ID
    NCT05728502
    Conditions
    Chronic Heart Failure With Reduced Ejection Fraction
    Interventions
    Vericiguat (Verquvo, BAY1021189); Standard of Care (SoC)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-04-25
    Completion
    2025-12-26
    Enrolment
    2,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure With Reduced Ejection Fraction
    InterventionVericiguat (Verquvo, BAY1021189); Standard of Care (SoC)
    PhaseNot recorded
    Registry statusCompleted

  • Strategy, Efficacy and Safety of Medication Usage in Heart Failure Patients Who Were Intolerable to GDMT

    NCT05799638 · start 2023-01-01

    Registered record
    Registry ID
    NCT05799638
    Conditions
    Heart Failure With Reduced Ejection Fraction
    Interventions
    Guideline-Directed Medication Treatment (GDMT)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-01-01
    Completion
    2024-06-30
    Enrolment
    263

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Reduced Ejection Fraction
    InterventionGuideline-Directed Medication Treatment (GDMT)
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)

    NCT05658458 · start 2022-12-16

    Registered record
    Registry ID
    NCT05658458
    Conditions
    Chronic Heart Failure With Reduced Ejection Fraction; Worsening Heart Failure
    Interventions
    Vericiguat (Verquvo, BAY1021189)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-12-16
    Completion
    2024-09-19
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure With Reduced Ejection Fraction; Worsening Heart Failure
    InterventionVericiguat (Verquvo, BAY1021189)
    PhasePhase 4
    Registry statusCompleted

  • A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions

    NCT05666518 · start 2022-08-31

    Registered record
    Registry ID
    NCT05666518
    Conditions
    Chronic Heart Failure
    Interventions
    Vericiguat (Verquvo, BAY1021189); Standard of care
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-08-31
    Completion
    2028-12-31
    Enrolment
    1,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure
    InterventionVericiguat (Verquvo, BAY1021189); Standard of care
    PhaseNot recorded
    Registry statusRecruiting

  • A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

    NCT05093933 · start 2021-11-02

    Registered record
    Registry ID
    NCT05093933
    Conditions
    Chronic Heart Failure With Reduced Ejection Fraction
    Interventions
    Vericiguat; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-11-02
    Completion
    2025-02-05
    Enrolment
    6,106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure With Reduced Ejection Fraction
    InterventionVericiguat; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately

    NCT05086952 · start 2021-10-12

    Registered record
    Registry ID
    NCT05086952
    Conditions
    Heart Failure; Children
    Interventions
    Vericiguat (BAY1021189) - Intervention A; Vericiguat (BAY1021189) - Intervention B; Vericiguat (BAY1021189) - Intervention C; Vericiguat (Verquvo, BAY1021189) - Intervention D
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-10-12
    Completion
    2022-02-15
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Children
    InterventionVericiguat (BAY1021189) - Intervention A; Vericiguat (BAY1021189) - Intervention B; Vericiguat (BAY1021189) - Intervention C; Vericiguat (Verquvo, BAY1021189) - Intervention D
    PhasePhase 1
    Registry statusCompleted

  • Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

    NCT03547583 · start 2018-06-15

    Registered record
    Registry ID
    NCT03547583
    Conditions
    Chronic Heart Failure With Preserved Ejection Fraction
    Interventions
    Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-06-15
    Completion
    2019-11-04
    Enrolment
    789

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure With Preserved Ejection Fraction
    InterventionVericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

    NCT03504982 · start 2018-05-17

    Registered record
    Registry ID
    NCT03504982
    Conditions
    Coronary Artery Disease
    Interventions
    Vericiguat (BAY1021189); Moxifloxacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-05-17
    Completion
    2019-02-26
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionVericiguat (BAY1021189); Moxifloxacin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients

    NCT03255512 · start 2017-08-17

    Registered record
    Registry ID
    NCT03255512
    Conditions
    Coronary Artery Disease
    Interventions
    Vericiguat (BAY1021189); Placebo; Isosorbide mononitrate (ISMN)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-08-17
    Completion
    2018-03-23
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionVericiguat (BAY1021189); Placebo; Isosorbide mononitrate (ISMN)
    PhasePhase 1
    Registry statusCompleted

  • Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects

    NCT03145038 · start 2017-05-16

    Registered record
    Registry ID
    NCT03145038
    Conditions
    Pharmacokinetics
    Interventions
    Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed; Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted; Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed; Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed; American breakfast; Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed; American breakfast; Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed; Continental breakfast
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-05-16
    Completion
    2017-10-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    InterventionVericiguat(BAY1021189, high-dose pediatric-formulation)_fed; Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted; Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed; Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed +5 more
    PhasePhase 1
    Registry statusCompleted

  • A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

    NCT02861534 · start 2016-09-20

    Registered record
    Registry ID
    NCT02861534
    Conditions
    Heart Failure; Chronic Heart Failure With Reduced Ejection Fraction
    Interventions
    Vericiguat; Placebo for vericiguat
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-09-20
    Completion
    2019-09-02
    Enrolment
    5,050

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Chronic Heart Failure With Reduced Ejection Fraction
    InterventionVericiguat; Placebo for vericiguat
    PhasePhase 3
    Registry statusCompleted